139 related articles for article (PubMed ID: 34962399)
1. Persistence Pays Off: Milvexian Emerges from the Industry's Longstanding Search for Orally Bioavailable Factor XIa Inhibitors.
Goodwin NC
J Med Chem; 2022 Feb; 65(3):1767-1769. PubMed ID: 34962399
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
Dilger AK; Pabbisetty KB; Corte JR; De Lucca I; Fang T; Yang W; Pinto DJP; Wang Y; Zhu Y; Mathur A; Li J; Hou X; Smith D; Sun D; Zhang H; Krishnananthan S; Wu DR; Myers JE; Sheriff S; Rossi KA; Chacko S; Zheng JJ; Galella MA; Ziemba T; Dierks EA; Bozarth JM; Wu Y; Crain E; Wong PC; Luettgen JM; Wexler RR; Ewing WR
J Med Chem; 2022 Feb; 65(3):1770-1785. PubMed ID: 34494428
[TBL] [Abstract][Full Text] [Related]
3. Milvexian for the Prevention of Venous Thromboembolism.
Weitz JI; Strony J; Ageno W; Gailani D; Hylek EM; Lassen MR; Mahaffey KW; Notani RS; Roberts R; Segers A; Raskob GE;
N Engl J Med; 2021 Dec; 385(23):2161-2172. PubMed ID: 34780683
[TBL] [Abstract][Full Text] [Related]
4. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
[TBL] [Abstract][Full Text] [Related]
5. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
[TBL] [Abstract][Full Text] [Related]
6. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.
Corte JR; Fang T; Pinto DJ; Orwat MJ; Rendina AR; Luettgen JM; Rossi KA; Wei A; Ramamurthy V; Myers JE; Sheriff S; Narayanan R; Harper TW; Zheng JJ; Li YX; Seiffert DA; Wexler RR; Quan ML
Bioorg Med Chem; 2016 May; 24(10):2257-72. PubMed ID: 27073051
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
Yang W; Wang Y; Lai A; Clark CG; Corte JR; Fang T; Gilligan PJ; Jeon Y; Pabbisetty KB; Rampulla RA; Mathur A; Kaspady M; Neithnadka PR; Arumugam A; Raju S; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Chacko SA; Bozarth JM; Wu Y; Crain EJ; Wong PC; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
J Med Chem; 2020 Jul; 63(13):7226-7242. PubMed ID: 32456431
[TBL] [Abstract][Full Text] [Related]
8. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
Corte JR; Pinto DJP; Fang T; Osuna H; Yang W; Wang Y; Lai A; Clark CG; Sun JH; Rampulla R; Mathur A; Kaspady M; Neithnadka PR; Li YC; Rossi KA; Myers JE; Sheriff S; Lou Z; Harper TW; Huang C; Zheng JJ; Bozarth JM; Wu Y; Wong PC; Crain EJ; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
J Med Chem; 2020 Jan; 63(2):784-803. PubMed ID: 31833761
[TBL] [Abstract][Full Text] [Related]
9. Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Fang T; Corte JR; Gilligan PJ; Jeon Y; Osuna H; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Wexler RR; Lam PYS
Bioorg Med Chem Lett; 2020 Feb; 30(4):126949. PubMed ID: 31932224
[TBL] [Abstract][Full Text] [Related]
10. Factor XIa as a possible new target of antithrombotic therapy.
Goto S
J Thromb Haemost; 2006 Jul; 4(7):1494-5. PubMed ID: 16839344
[No Abstract] [Full Text] [Related]
11. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.
Clark CG; Rossi KA; Corte JR; Fang T; Smallheer JM; De Lucca I; Nirschl DS; Orwat MJ; Pinto DJP; Hu Z; Wang Y; Yang W; Jeon Y; Ewing WR; Myers JE; Sheriff S; Lou Z; Bozarth JM; Wu Y; Rendina A; Harper T; Zheng J; Xin B; Xiang Q; Luettgen JM; Seiffert DA; Wexler RR; Lam PYS
Bioorg Med Chem Lett; 2019 Oct; 29(19):126604. PubMed ID: 31445854
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.
Lorthiois E; Roache J; Barnes-Seeman D; Altmann E; Hassiepen U; Turner G; Duvadie R; Hornak V; Karki RG; Schiering N; Weihofen WA; Perruccio F; Calhoun A; Fazal T; Dedic D; Durand C; Dussauge S; Fettis K; Tritsch F; Dentel C; Druet A; Liu D; Kirman L; Lachal J; Namoto K; Bevan D; Mo R; Monnet G; Muller L; Zessis R; Huang X; Lindsley L; Currie T; Chiu YH; Fridrich C; Delgado P; Wang S; Hollis-Symynkywicz M; Berghausen J; Williams E; Liu H; Liang G; Kim H; Hoffmann P; Hein A; Ramage P; D'Arcy A; Harlfinger S; Renatus M; Ruedisser S; Feldman D; Elliott J; Sedrani R; Maibaum J; Adams CM
J Med Chem; 2020 Aug; 63(15):8088-8113. PubMed ID: 32551603
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.
Schumacher WA; Seiler SE; Steinbacher TE; Stewart AB; Bostwick JS; Hartl KS; Liu EC; Ogletree ML
Eur J Pharmacol; 2007 Sep; 570(1-3):167-74. PubMed ID: 17597608
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.
Pinto DJ; Smallheer JM; Corte JR; Austin EJ; Wang C; Fang T; Smith LM; Rossi KA; Rendina AR; Bozarth JM; Zhang G; Wei A; Ramamurthy V; Sheriff S; Myers JE; Morin PE; Luettgen JM; Seiffert DA; Quan ML; Wexler RR
Bioorg Med Chem Lett; 2015 Apr; 25(7):1635-42. PubMed ID: 25728130
[TBL] [Abstract][Full Text] [Related]
15. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.
Hu Z; Wang C; Han W; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2018 Apr; 28(6):987-992. PubMed ID: 29501396
[TBL] [Abstract][Full Text] [Related]
16. Factor XIa Inhibitors as New Anticoagulants.
Quan ML; Pinto DJP; Smallheer JM; Ewing WR; Rossi KA; Luettgen JM; Seiffert DA; Wexler RR
J Med Chem; 2018 Sep; 61(17):7425-7447. PubMed ID: 29775297
[TBL] [Abstract][Full Text] [Related]
17. Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.
Corte JR; Yang W; Fang T; Wang Y; Osuna H; Lai A; Ewing WR; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Quan ML; Wexler RR; Lam PYS
Bioorg Med Chem Lett; 2017 Aug; 27(16):3833-3839. PubMed ID: 28687203
[TBL] [Abstract][Full Text] [Related]
18. Factor XI as a Therapeutic Target.
Gailani D; Gruber A
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.
Hussain Z; Cooke AJ; Neelamkavil S; Brown L; Carswell E; Geissler WM; Guo Z; Hawes B; Kelly TM; Kiyoi Y; Lai K; Lesburg C; Pow E; Zang Y; Wood HB; Edmondson SD; Liu W
Bioorg Med Chem Lett; 2020 Aug; 30(16):127072. PubMed ID: 32340773
[TBL] [Abstract][Full Text] [Related]
20. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Cohen-Williams ME; Varty GB; Tulshian DB
Bioorg Med Chem Lett; 2005 Aug; 15(16):3670-4. PubMed ID: 15978806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
